To include your compound in the COVID-19 Resource Center, submit it here.

Nabel leaves Moderna’s board to avoid conflict-of-interest concerns; plus changes at Genespire, La Jolla, Editas and more

mRNA company Moderna Inc. (NASDAQ:MRNA) said Elizabeth Nabel has resigned from its board to avoid any potential or apparent conflict of interest. She is president of Brigham and Women’s Hospital, a site enrolling patients in the Phase III trial of Moderna’s COVID-19 vaccine, mRNA-1273. Nabel is also

Read the full 477 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE